ADx scientists have developed several new biomarkers based on its own proprietary antibodies. Two of them are new synaptic biomarkers: SNAP25 and Neuronal Pentraxin 2 (NPTX2).
For SNAP25, a high sensitive platform is needed while a NPTX2 measurment can be done with a simple ELISA.
ADx has also two new monoclonal antibodies that can measure Neurofilament Light in CSF with ELISA.
Further on, we are pursuing the the validation of the measurment of Beta Amyloid 42/40 in blood: A promising test for detecting Amyloid plaque burden in the brain.